Clinical trials: Prophylaxis of Venous Thromboembolism
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
- Trial name
- NCT00913120
- Testing
- YM150, Enoxaparin
- Where
- 16 sites in Japan, South Korea and 2 more
- Volunteers
- 610 people
- Sponsor
- Astellas Pharma Inc
Venous Thromboembolism, Arthroplasty, Replacement
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
an open, prospective, observational study to collect data on safety (major bleeding events) and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to dabigatran etexilate in patients with total knee…
- Trial name
- NCT01153698
- Testing
- dabigatran
- Where
- 7 sites in Austria
- Volunteers
- 167 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Knee Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01206972
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 33 sites in Japan
- Volunteers
- 302 people
- Sponsor
- Bayer
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total knee replacement surgery.
- Trial name
- NCT00917254
- Testing
- YM150, Enoxaparin
- Where
- 13 sites in Japan, Taiwan and 1 more
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Prevention of Venous Thromboembolism
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.
Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study.
- Trial name
- PRO-LAPSII (NCT03055026)
- Testing
- Rivaroxaban
- Where
- 17 sites in Italy
- Volunteers
- 582 people
- Sponsor
- Fadoi Foundation, Italy
Hematologic Neoplasm, Acute Leukemia
PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism
The primary objective of the study is to assess efficacy and safety of different prophylactic or therapeutic antithrombotic approaches in patients with hematologic neoplasms and platelet count <50 x109/L, including unfractionated…
- Conditions
- Hematologic Neoplasm, Acute Leukemia, Myelodysplastic Syndrome, Lymphoma
- Trial name
- NCT01855698
- Testing
- Observation
- Where
- 23 sites in Italy
- Volunteers
- 99 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Venous Thromboembolism (VTE)
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery.
- Trial name
- ROXI-APEX (NCT07015905)
- Testing
- REGN7508, Apixaban, Enoxaparin
- Where
- 47 sites in United States, Bulgaria and 6 more
- Volunteers
- 2,000 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism, Anticoagulant
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal…
- Conditions
- Venous Thromboembolism, Anticoagulant, Elderly
- Trial name
- Jason (NCT04257487)
- Testing
- Sulodexide
- Where
- Italy
- Volunteers
- 1,455 people
- Sponsor
- Arianna Anticoagulazione Foundation
Thrombotic Disorders
Prevention of Thromboembolic Events in Total Knee Replacement Patients
The purpose of the study is to find out whether MAA868, is able to prevent blood clots following your medical condition (surgery for knee replacement)
- Trial name
- NCT03393481
- Testing
- MAA868, Enoxaparin
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism
Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)
This study was designed to assess the safety and efficacy of GW813893 in the prophylaxis of VTE following TKR and to provide evidence to enable the selection of the appropriate dose(s) and dose regimen of GW813893 for future…
- Trial name
- NCT00541320
- Testing
- GW813893
- Where
- 8 sites in United States
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
This is a pilot study to evaluate safety of fondaparinux and enoxaparin in terms of bleeding and development of thrombocytopenia in the medical ICU population.
- Trial name
- NCT00493896
- Testing
- Fondaparinux, Enoxaparin
- Volunteers
- 27 people
- Sponsor
- Eastern Virginia Medical School
Prevention of Venous Thromboembolism
Efficacy of the Use of Risk Scores in Reducing Important Clinical Outcomes in Hospitalized Medical Ill Patients
FADOI (Italian Scientific Society of Hospital Internal Medicine) has planned to promote a multicenter cluster-randomized controlled clinical study in order to evaluate the effects of a systematic assessment of patients by using…
- Trial name
- RICO (NCT04267718)
- Testing
- Application of Padua and IMPROVE Bleeding scores
- Where
- 35 sites in Italy
- Volunteers
- 2,878 people
- Sponsor
- Fadoi Foundation, Italy
Atrial Fibrillation, Cardioembolic Events
Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
Oral anticoagulation treatment (OAC) following clinically successful catheter abla-tion of atrial fibrillation (AF) is controversial.
- Conditions
- Atrial Fibrillation, Cardioembolic Events, Oral Anticoagulation
- Trial name
- ODIn-AF (NCT02067182)
- Testing
- Dabigatran
- Where
- 19 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Georg Nickenig
High Bleeding Risk, Hemorrhage
Efficacy of Intermittent Pneumatic Compression (IPC) on Venous Thromboembolism Incidence in Intensive Care Unit (ICU) Patients With High Bleeding Risk
This multicentre open-label randomized parallel-group trial aims to evaluate the association intermittent pneumatic compression + elastick stockings versus elasting stockings alone on symptomatic or asymptomatic venous…
- Trial name
- CIREA1 (NCT00740844)
- Testing
- Intermittent pneumatic compression of the lower limbs
- Where
- 10 sites in France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Brest
Critical Illness, Therapeutic Drug Monitoring
Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients
Primary objective The objective of this study is to compare anti-Xa levels obtained with a standard high dose thrombosis prophylaxis in COVID-19 intensive care-patients compared with anti-Xa levels obtained with a normal dose…
- Conditions
- Critical Illness, Therapeutic Drug Monitoring, Venous Thromboembolism
- Trial name
- NADRO (NCT05926518)
- Testing
- blood sampling
- Where
- Netherlands
- Volunteers
- 62 people
- Sponsor
- Rijnstate Hospital
Venous Thrombosis and Pulmonary Embolism
A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
- Trial name
- COSIMO (NCT02742623)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- 10 sites in Australia, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Bayer
Venous Thromboembolism
A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
The purpose of the study is to evaluate the efficacy and safety of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients undergoing major abdominal surgery.
- Trial name
- NCT00942435
- Testing
- YM150, mechanical prophylaxis
- Where
- 6 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Astellas Pharma Inc
Colorectal Cancer
A Study of Enhancing Drug Prophylaxis of Venous Thromboembolism in Chinese Colorectal Cancer Surgery
This project intends to conduct a multicenter, prospective, observational cohort study, aiming to explore the impact of the timing of pharmacological thromboprophylaxis initiation on postoperative bleeding risk and the…
- Trial name
- E-DISTANCE (NCT06513481)
- Testing
- Nardraparin calcium injection
- Volunteers
- 914 people
- Sponsor
- RenJi Hospital
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi